Patel Jeegar Pravinkumar 4

What Happened
Jeegar Patel, Chief Scientific Officer of Evommune (EVMN), exercised 1,488 stock options at $3.84 per share (cost $5,714) and sold those 1,488 shares in the open market at $22.50 per share for gross proceeds of $33,480 on 2026-06-22. The filing also shows a related derivative disposition recorded at $0.00 (see Key Details). The transactions were executed under a Rule 10b5-1 trading plan.

Key Details

• Transaction date: 2026-06-22; Form 4 filed: 2026-06-24 (appears timely).
• Exercise: 1,488 shares (code M) acquired at $3.84 each — total exercise cost $5,714.
• Sale: 1,488 shares (code S) sold at $22.50 each — total proceeds $33,480.
• Net proceeds (sale minus exercise cost): $33,480 − $5,714 = $27,766 (before taxes/fees).
• Derivative entry: 1,488 shares reported disposed at $0.00 — often used to report shares withheld/surrendered in connection with exercise or tax obligations.
• Shares owned after the transactions: not specified in the provided filing excerpt.
• Footnotes: F1 — transactions were pursuant to a Rule 10b5-1 plan adopted Feb 27, 2026; F2 — option vesting schedule (1/4 after one year, then monthly over 36 months).
• Transaction codes: M = option exercise/conversion, S = sale.

Context
Because the shares were exercised and then sold the same day, this effectively functions as a cashless exercise + immediate sale (routine monetization). Sales by insiders are common and do not by themselves indicate a change in company outlook; purchases tend to be more informative for bullish signals. The $0.00 derivative disposition typically reflects withholding or surrender of shares to cover taxes or option-related costs.